High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP

High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP

IntroductionNon-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) is the standard treatment regimen for NHL, yielding a complete remission (CR) rate of...

Full description

Bibliographic Details
Main Authors: Sukanya Dhar, Mohona Chakravarti, Nilanjan Ganguly, Akata Saha, Shayani Dasgupta, Saurav Bera, Anirban Sarkar, Kamalika Roy, Juhina Das, Avishek Bhuniya, Sarbari Ghosh, Madhurima Sarkar, Srabanti Hajra, Saptak Banerjee, Chiranjib Pal, Bhaskar Saha, Kalyan Kusum Mukherjee, Rathindranath Baral, Anamika Bose
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
cancer recurrence
IL-6/IL-10/IL-1β
multi-drug resistance
myeloid derived suppressor cells
non-Hodgkin lymphoma
therapy resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303959/full

Similar Items